

CITATION REPORT

List of articles citing

Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)

DOI: 10.7759/cureus.7343
Cureus, 2020, 12, e7343.

Source: <https://exaly.com/paper-pdf/90775316/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 66 | COVID-19 Lung Injury and High-Altitude Pulmonary Edema. A False Equation with Dangerous Implications. <i>Annals of the American Thoracic Society</i> , 2020 , 17, 918-921 | 4.7 | 31 |
| 65 | Inpatient obstetric management of COVID-19. <i>Seminars in Perinatology</i> , 2020 , 44, 151280 | 3.3 | 4 |
| 64 | Evaluation of PEEP and prone positioning in early COVID-19 ARDS. <i>EClinicalMedicine</i> , 2020 , 28, 100579 | 11.3 | 26 |
| 63 | Cancer Care Management During the COVID-19 Pandemic. <i>Risk Management and Healthcare Policy</i> , 2020 , 13, 1711-1721 | 2.8 | 7 |
| 62 | Lessons from dermatology about inflammatory responses in Covid-19. <i>Reviews in Medical Virology</i> , 2020 , 30, e2130 | 11.7 | 20 |
| 61 | nSARS-Cov-2, pulmonary edema and thrombosis: possible molecular insights using miRNA-gene circuits in regulatory networks. <i>ExRNA</i> , 2020 , 2, 16 | 4.2 | 1 |
| 60 | Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension. <i>Diagnostics</i> , 2020 , 10, | 3.8 | 12 |
| 59 | Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. <i>Biochemical Pharmacology</i> , 2020 , 180, 114169 | 6 | 19 |
| 58 | Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?. <i>International Journal of Molecular Sciences</i> , 2020 , 21, | 6.3 | 22 |
| 57 | Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. <i>International Journal of Molecular Sciences</i> , 2020 , 21, | 6.3 | 6 |
| 56 | Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review. <i>SN Comprehensive Clinical Medicine</i> , 2020 , 2, 1-11 | 2.7 | 15 |
| 55 | Hypothesis: The potential therapeutic role of nicorandil in COVID-19. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2020 , 47, 1791-1797 | 3 | 3 |
| 54 | Emerging Mechanisms of Pulmonary Vasoconstriction in SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) and Potential Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2020 , 21, | 6.3 | 17 |
| 53 | A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection. <i>Infection, Genetics and Evolution</i> , 2020 , 86, 104610 | 4.5 | 13 |
| 52 | Comment on Melatonin as a potential adjuvant treatment for COVID-19. <i>Life Sciences</i> , 2020 , 253, 117739.8 | 9.8 | 11 |
| 51 | Two important controversial risk factors in SARS-CoV-2 infection: Obesity and smoking. <i>Environmental Toxicology and Pharmacology</i> , 2020 , 78, 103411 | 5.8 | 92 |
| 50 | To compare the incomparable: COVID-19 pneumonia and high-altitude disease. <i>European Respiratory Journal</i> , 2020 , 55, | 13.6 | 9 |

| | | | |
|----|---|------|-----|
| 49 | Using applied lung physiology to understand COVID-19 patterns. <i>British Journal of Anaesthesia</i> , 2020 , 125, 250-253 | 5.4 | 12 |
| 48 | COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. <i>Clinics and Practice</i> , 2020 , 10, 1271 | 2.4 | 185 |
| 47 | Impaired cardiac function is associated with mortality in patients with acute COVID-19 infection. <i>Clinical Research in Cardiology</i> , 2020 , 109, 1491-1499 | 6.1 | 74 |
| 46 | Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019. <i>Immunotherapy</i> , 2020 , 12, 1121-1126 | 3.8 | 14 |
| 45 | Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?. <i>Respiratory Physiology and Neurobiology</i> , 2020 , 279, 103476 | 2.8 | 33 |
| 44 | SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020 , 1866, 165889 | 6.9 | 38 |
| 43 | Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. <i>Reviews in Medical Virology</i> , 2020 , 30, e2136 | 11.7 | 10 |
| 42 | COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection. <i>Journal of Clinical Medicine</i> , 2020 , 9, | 5.1 | 77 |
| 41 | Pulmonary Vascular Manifestations of COVID-19 Pneumonia. <i>Radiology: Cardiothoracic Imaging</i> , 2020 , 2, e200277 | 8.3 | 70 |
| 40 | Corticosteroid Guidance for Pregnancy during COVID-19 Pandemic. <i>American Journal of Perinatology</i> , 2020 , 37, 809-812 | 3.3 | 24 |
| 39 | COVID-19 Lung Injury is Not High Altitude Pulmonary Edema. <i>High Altitude Medicine and Biology</i> , 2020 , 21, 192-193 | 1.9 | 29 |
| 38 | Respiratory conditions in coronavirus disease 2019 (COVID-19): Important considerations regarding novel treatment strategies to reduce mortality. <i>Medical Hypotheses</i> , 2020 , 140, 109760 | 3.8 | 48 |
| 37 | Vascular endothelial injury exacerbates coronavirus disease 2019: The role of endothelial glycocalyx protection. <i>Microcirculation</i> , 2021 , 28, e12654 | 2.9 | 28 |
| 36 | Protease inhibitors targeting the main protease and papain-like protease of coronaviruses. <i>Expert Opinion on Therapeutic Patents</i> , 2021 , 31, 309-324 | 6.8 | 13 |
| 35 | Evidence-Based Management of the Critically Ill Adult With SARS-CoV-2 Infection. <i>Journal of Intensive Care Medicine</i> , 2021 , 36, 18-41 | 3.3 | 5 |
| 34 | The Role of Phosphodiesterase-5 Inhibitors in COVID-19: An Exploration of Literature From Similar Pathologies. <i>Journal of Intensive Care Medicine</i> , 2021 , 36, 3-8 | 3.3 | 3 |
| 33 | The ACE2 as a "rescue protein" or "suspect enzyme" in COVID-19: possible application of the "engineered inactive hACE2" as a safer therapeutic agent in the treatment of SARS-CoV-2 infection. <i>Journal of the Iranian Chemical Society</i> , 2021 , 18, 495-502 | 2 | 4 |
| 32 | COVID-19 and Pneumolysis Simulating Extreme High-altitude Exposure with Altered Oxygen Transport Physiology; Multiple Diseases, and Scarce Need of Ventilators: Andean Condor's-eye-view. <i>Reviews on Recent Clinical Trials</i> , 2020 , 15, 347-359 | 1.2 | 8 |

| | | | |
|----|---|-----|----|
| 31 | Predictive medicinal metabolites from against comorbidity related proteins of SARS-CoV-2 infections. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021 , 1-14 | 3.6 | 2 |
| 30 | Is carbonic anhydrase inhibition useful as a complementary therapy of Covid-19 infection?. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021 , 36, 1230-1235 | 5.6 | 9 |
| 29 | Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities. <i>Pharmaceutics</i> , 2021 , 13, | 6.4 | 11 |
| 28 | Anti-infection mechanism of phosphodiesterase-5 inhibitors and their roles in coronavirus disease 2019 (Review). <i>Experimental and Therapeutic Medicine</i> , 2021 , 21, 320 | 2.1 | |
| 27 | The Fundamentals of Respiratory Physiology to Manage the COVID-19 Pandemic: An Overview. <i>Frontiers in Physiology</i> , 2020 , 11, 615690 | 4.6 | 3 |
| 26 | Dynamic monitoring of serum liver function indexes in patients with COVID-19. <i>World Journal of Clinical Cases</i> , 2021 , 9, 1554-1562 | 1.6 | 1 |
| 25 | Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics. <i>Pharmaceutics</i> , 2021 , 13, | 6.4 | 11 |
| 24 | Cardiovascular protective properties of oxytocin against COVID-19. <i>Life Sciences</i> , 2021 , 270, 119130 | 6.8 | 12 |
| 23 | Do fluorocarbons substantially increase transdermal oxygen delivery? A proof-of-principle study in mice. <i>Open Research Europe</i> , 1, 39 | | |
| 22 | Relating Ventilatory Support and Drug Treatment Strategies to the Fundamental Pathophysiology in COVID-19 Illness. <i>European Medical Journal (Chelmsford, England)</i> , | 7.5 | |
| 21 | Relating Ventilatory Support and Drug Treatment Strategies to the Fundamental Pathophysiology in COVID-19 Illness. <i>European Medical Journal (Chelmsford, England)</i> , | 7.5 | |
| 20 | A Recent Update on Therapeutics to Treat Emerging n-COVID 19: A Review. <i>Coronaviruses</i> , 2021 , 2, | 1.5 | 0 |
| 19 | Do fluorocarbons substantially increase transdermal oxygen delivery? A proof-of-principle study in mice. <i>Open Research Europe</i> , 1, 39 | | |
| 18 | Forty-fifth ASPEN Presidential Address: Research in a pandemic-Why, what, how?. <i>Journal of Parenteral and Enteral Nutrition</i> , 2021 , 45, 1690-1702 | 4.2 | 1 |
| 17 | A Comprehensive Summary of the Knowledge on COVID-19 Treatment. 2021 , 12, 155-191 | | 13 |
| 16 | A transcription regulatory network within the ACE2 locus may promote a pro-viral environment for SARS-CoV-2 by modulating expression of host factors. | | 10 |
| 15 | Obesity and Smoking as Risk Factors for Invasive Mechanical Ventilation in COVID-19: a Retrospective, Observational Cohort Study. 2020 , | | 5 |
| 14 | Obesity and smoking as risk factors for invasive mechanical ventilation in COVID-19: A retrospective, observational cohort study. <i>PLoS ONE</i> , 2020 , 15, e0238552 | 3.7 | 21 |

| | | | |
|----|--|-----|----|
| 13 | Altitude and COVID-19: Friend or foe? A narrative review. <i>Physiological Reports</i> , 2021 , 8, e14615 | 2.6 | 19 |
| 12 | Drug Repurposing for COVID-19 using Graph Neural Network with Genetic, Mechanistic, and Epidemiological Validation. 2020 , | | 13 |
| 11 | Assessment and treatment of older individuals with COVID 19 multi-system disease: Clinical and ethical implications. <i>Acta Biomedica</i> , 2020 , 91, 150-168 | 3.2 | 10 |
| 10 | COVID-19: An Archetype Innate Immunity Reaction and Modes of Treatment. <i>Mediterranean Journal of Rheumatology</i> , 2020 , 31, 275-283 | 1.4 | 2 |
| 9 | COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors. <i>Journal of Microscopy and Ultrastructure</i> , 2020 , 8, 141-145 | 0.9 | 12 |
| 8 | COULD COVID-19 BE A HEMOGLOBINOPATHY?. <i>Acta Clinica Croatica</i> , 2020 , 59, 740-744 | 0.8 | 2 |
| 7 | Treatment and prognosis of COVID-19: Current scenario and prospects (Review). <i>Experimental and Therapeutic Medicine</i> , 2021 , 21, 3 | 2.1 | 3 |
| 6 | Treatment and prognosis of COVID-19: Current scenario and prospects (Review). <i>Experimental and Therapeutic Medicine</i> , 2020 , 20, 1-1 | 2.1 | 9 |
| 5 | COVID-19, Cation Dysmetabolism, Sialic Acid, CD147, ACE2, Viroporins, Hepcidin and Ferroptosis: A Possible Unifying Hypothesis.. <i>F1000Research</i> , 2022 , 11, 102 | 3.6 | 2 |
| 4 | Multidimensional in silico strategy for identification of natural polyphenols-based SARS-CoV-2 main protease (M) inhibitors to unveil a hope against COVID-19.. <i>Computers in Biology and Medicine</i> , 2022 , 145, 105452 | 7 | 4 |
| 3 | SARS-CoV-2 Infection Dysregulates Host Iron (Fe)-Redox Homeostasis (Fe-R-H): Role of Fe-Redox Regulators, Ferroptosis Inhibitors, Anticoagulants, and Iron-Chelators in COVID-19 Control. <i>Journal of Dietary Supplements</i> , 1-60 | 2.3 | 0 |
| 2 | The role of calcium and calcium regulating hormonal system in the mechanisms of COVID-19 contagiousness and severity. 2022 , 14-22 | | 0 |
| 1 | Disparities in COVID-19 incidence and fatality rates at high-altitude. 11, e14473 | | 0 |